Opportunities for Healthy Volunteers

Contribute to medical research by participating in studies designed for healthy participants in your selected area.

Matched clinical trials

  • A Study of Zanidatamab for Patients with Previously Treated HER2-Expressing Solid Tumors

    Recruiting

    2 1 1
    Investigated Drugs:
    Spain
  • A Study of BNT323 and BNT327 for Patients with Advanced Breast Cancer to Test Safety and Effectiveness

    Recruiting

    1 1 1
    Investigated Drugs:
    France Italy Spain
  • Comparing magnesium sulfate and dexmedetomidine combined with ropivacaine for pain relief after breast cancer surgery in women undergoing mastectomy

    Recruiting

    3 1 1 1
    Investigated Diseases:
    Spain
  • A Study of Datopotamab Deruxtecan for Patients with Hormone Receptor-Positive, HER2-Negative Advanced or Metastatic Breast Cancer That Did Not Respond to Hormone Therapy

    Recruiting

    2 1 1
    Investigated Drugs:
    France Italy Spain
  • Study of PF-07248144 and fulvestrant in adults with hormone receptor-positive, HER2-negative advanced or metastatic breast cancer who had progression after CDK4/6 inhibitor therapy

    Recruiting

    3 1 1 1
    Belgium Bulgaria Czechia Finland France Germany +8
  • Study of Izalontamab Brengitecan Compared to Standard Chemotherapy in Untreated Triple-negative or ER-low, HER2-negative Breast Cancer Patients Not Eligible for Anti-PD1/PD-L1 Treatment

    Recruiting

    4 1 1 1
    Austria France Germany Greece Italy Poland +4
  • Study of typology-based coaching and education to help patients with early hormone-positive HER2-negative breast cancer manage their treatment with ribociclib

    Recruiting

    3 1 1 1
    Investigated Drugs:
    Germany
  • Evaluating Elacestrant alone or with leuprorelin in premenopausal women with early-stage hormone receptor positive breast cancer before surgery

    Recruiting

    2 1 1 1
    France
  • Study of MK-5684 compared to standard therapy in patients with breast cancer, ovarian cancer, or endometrial cancer

    Recruiting

    4 1 1 1
    Spain
  • Long-term safety study of GD2IL18CART treatment in patients with neuroblastoma, osteosarcoma, Ewing sarcoma, or advanced breast cancer

    Recruiting

    1 1 1
    Investigated Drugs:
    Germany